Guided Therapeutics (OTCMKTS:GTHP – Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.01) earnings per share (EPS) for the quarter, Zacks reports.
Guided Therapeutics Stock Performance
OTCMKTS GTHP remained flat at $0.29 on Thursday. 1 shares of the company traded hands, compared to its average volume of 5,585. The stock has a market capitalization of $28.00 million, a P/E ratio of -7.25 and a beta of 0.71. Guided Therapeutics has a fifty-two week low of $0.15 and a fifty-two week high of $0.54. The stock’s 50 day moving average is $0.26 and its two-hundred day moving average is $0.27.
Guided Therapeutics Company Profile
Guided Therapeutics, Inc is a medical device company focused on the development and commercialization of non‐invasive optical diagnostic platforms for women’s health. Its flagship product, the LuViva® Advanced Cervical Scan, combines hyperspectral and reflectance imaging to support the early detection of cervical epithelial abnormalities. By capturing tissue fluorescence and reflectance signatures in real time, LuViva is designed to augment traditional visual inspection methods and assist clinicians during colposcopic evaluations.
The company secured 510(k) clearance from the U.S.
Featured Stories
- Five stocks we like better than Guided Therapeutics
- Nebius Just Exploded 34% on Blowout Earnings—Is It Time to Buy?
- Joby’s Defense Pivot Accelerates With $500M Resonant Sciences Deal
- Lumentum Just Delivered the AI Growth Investors Wanted
- Ryman Checks Into a $1.38B Hospitality Upgrade
Receive News & Ratings for Guided Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guided Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
